What is Novartis AG’s presence in India?
On July 29, 2026, Novartis AG divested Novartis India Limited (NIL). Following the divestment, Novartis Healthcare Private Limited (NHPL), also referred to as Novartis India, remains Novartis AG’s sole operating entity in India.
Is Novartis India the same as Novartis Healthcare Private Limited (NHPL)?
Yes. Novartis Healthcare Private Limited (NHPL), operating as Novartis India, is Novartis AG’s sole operating entity in India.
Following the divestment of Novartis India Limited (NIL), NHPL continues to lead Novartis AG’s innovative medicines business in the country.
Through NHPL, Novartis continues to serve patients, collaborate with healthcare stakeholders, and advance healthcare innovation in India.
What is Novartis' footprint in India?
Novartis has been a trusted partner in India's healthcare ecosystem since 1947 and remains committed to advancing healthcare through science, innovation, and partnerships that help address the country's evolving health needs.
Through Novartis India, legally known as Novartis Healthcare Private Limited (NHPL), Novartis has an integrated footprint across Research & Development, Operations, and Commercial.
India plays a critical role in Novartis’ global network and is among the few countries where the company operates across the full value chain. More than 9,000 employees contribute across research, development, manufacturing, operations, and commercial functions.
Together, our people harness science and innovation to reimagine what is possible for patients today and tomorrow.
What are Novartis India's key areas of focus?
Novartis focuses on addressing some of India’s most pressing health challenges through its innovative portfolio in cardiology, oncology, immunology, and neuroscience, while working to enable faster patient access to medicines. The recent introduction of India’s first regulatory authority-approved radioligand therapy (RLT) for eligible patients with prostate cancer marked a significant milestone in bringing cutting-edge innovation to the country. Other current priorities include advancing the immunology pipeline with an advanced medicine for chronic spontaneous urticaria, alongside earlier intervention in atherosclerotic cardiovascular disease using siRNA and approaches targeting lipoprotein(a).
What is Novartis India's long-term commitment to India?
India remains an important market and a key capability and innovation hub for Novartis. Novartis India continues to focus on bringing innovative medicines to patients, supporting research and development, and contributing to the broader healthcare ecosystem in India.
The recent milestone marking 25 years of the Novartis Corporate Center (NOCC) in Hyderabad reflects the company’s long-standing investment in India’s talent, innovation ecosystem, and healthcare future.
India remains a strategic priority for Novartis AG and a key hub for innovation, talent, and operations. For over 80 years, Novartis India has been a trusted partner in India’s healthcare ecosystem, and our commitment to the country remains steadfast. As a focused innovative medicines company, we are dedicated to bringing transformative medicines to patients faster, fostering collaboration across the healthcare ecosystem, and helping to improve and extend people’s lives.
Are Novartis medicines still available in India?
Yes.
Novartis India remains committed to serving patients and supporting healthcare professionals across the country.
Novartis medicines continue to be available in India through Novartis or its partners.
Patients with questions about their treatment should consult their healthcare professional.
Who is the Managing Director and Country President of Novartis India?
Amitabh Dube is the Managing Director and Country President of Novartis India.
Supported by the leadership team, he leads Novartis India’s operations and represents the company in India.
Why work at Novartis India?
At Novartis India, associates help reimagine medicine to improve and extend people’s lives.
Novartis fosters a culture in which our people are curious, inspired, empowered, and committed to working with integrity, while enabling employees to contribute to scientific advancement and positive patient outcomes.
Has Novartis India's name changed?
Novartis AG divested Novartis India Limited (NIL) on July 29, 2026. Following the change in ownership, NIL was renamed Evonile Pharma Limited. This change relates solely to that separate legal entity and does not affect Novartis Healthcare Private Limited (NHPL), through which Novartis India continues its operations in India as Novartis AG’s sole operating entity and leads its innovative medicines business.